Rapidly Expanded EBV-Specific T Cells for the Treatment of Refractory EBV Reactivation and EBV-Related Lymphoproliferative Disorders
These results strengthen previously published results using VSTs from healthy donors and further support the development of EBV-specific T cell therapies to treat refractory EBV reactivation and EBV-associated malignancies, particularly in transplant recipients.
Authors
- Isabelle Fleury (ORCID: https://orcid.org/0000-0002-9301-4748)
- Camille Tremblay‐Laganière (ORCID: https://orcid.org/0009-0000-8337-2122)
- Stéphanie Thiant (ORCID: https://orcid.org/0009-0002-7950-9354)
- G. Sauvageau
- Olivier Veilleux (ORCID: https://orcid.org/0000-0002-7029-1769)
- Imran Ahmad
- Caroline Lamarche (ORCID: https://orcid.org/0000-0002-9704-1241)
- P. Teira
- Lynne Senécal (ORCID: https://orcid.org/0000-0002-7629-9980)
- Cynthia Thérien
- Suzon Collette (ORCID: https://orcid.org/0000-0003-0234-4520)
- Nadia M. Bambace
- Cédric Carli
- Lorne Schweitzer (ORCID: https://orcid.org/0000-0003-0552-7875)
- Simon F. Dufresne (ORCID: https://orcid.org/0000-0002-2486-5813)
- Julie Orio
- Julien Patenaude
- Michel Duval
- Léa Bernard
- Martin Giroux
- Thomas Kiss
- Denis-Claude Roy
- Gabrielle Boudreau
- Sylvie Lachance
- Jean Roy
- Lambert Busque
- Sandra Cohen
- Jean-Sébastien Delisle
- Henrique Bittencourt
Institutions
- McGill University Health Centre (CA)
- Centre Hospitalier Universitaire Sainte-Justine (CA)
- Hôpital Maisonneuve-Rosemont (CA)
- Université de Montréal (CA)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2025-12-26
- DOI
- https://doi.org/10.1093/ofid/ofag006
- Primary Topic
- Viral-associated cancers and disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00